Team work matters: dual inhibition puts non-hodgkin lymphoma under siege

Clin Cancer Res. 2014 Dec 1;20(23):5863-5. doi: 10.1158/1078-0432.CCR-14-2055. Epub 2014 Oct 7.

Abstract

Inhibitors of PI3K/mTOR and histone deacetylases (HDAC) are effective in non-Hodgkin lymphoma (NHL). However, clinical resistance eventually ensues and combinatory therapies are sought to prevent it. Preclinical evaluation of dual PI3K/mTOR and HDAC inhibition is synergistic against NHL, paving the way for bench-to-bedside translation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Female
  • Humans
  • Hydroxamic Acids / administration & dosage*
  • Imidazoles / administration & dosage*
  • Indoles / administration & dosage*
  • Lymphoma, Large B-Cell, Diffuse / metabolism*
  • Quinolines / administration & dosage*
  • Signal Transduction / drug effects*

Substances

  • Hydroxamic Acids
  • Imidazoles
  • Indoles
  • Quinolines